SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced the publication of a new paper in Retina: The Journal of Retinal and Vitreous Diseases evaluating the safety and tolerability of ACU-4429, a novel, small-molecule visual cycle modulator (VCM). The paper was co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, along with collaborators from Retina Foundation of the Southwest and Otsuka Pharmaceutical, and details the first-time demonstration of a non-retinoid therapeutic in a convenient, oral pill form effectively targeting the visual cycle in a dose-dependent manner.
